Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Delayed Data from NSDQ)

$15.20 USD

15.20
1,520,024

-0.34 (-2.19%)

Updated May 24, 2024 04:00 PM ET

After-Market: $15.21 +0.01 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ACAD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

ACADIA Pharmaceuticals Inc. [ACAD]

Reports for Purchase

Showing records 121 - 140 ( 240 total )

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 121

04/07/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 122

04/06/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 123

03/24/2020

Industry Report

Pages: 15

COVID-19 and Clinical Trials: A Combo That Doesn''t Mix?

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 124

03/04/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 125

02/27/2020

Company Report

Pages: 7

Persistent Nuplazid Growth Complemented by Pimavanserin Catalysts Approaching in 2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 126

02/20/2020

Company Report

Pages: 7

Looking Ahead to 2020 Catalysts With Anticipated Milestones for Pimavanserin Development

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 127

02/13/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 128

02/10/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 129

01/09/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 130

01/03/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 131

12/05/2019

Daily Note

Pages: 4

Pimavanserin Phase 3 HARMONY Trial Topline Meets Primary and Key Secondary Endpoint at CTAD?19

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 132

11/26/2019

Daily Note

Pages: 3

ADVANCE Topline Win Adds Momentum to Indication Expansion Endeavour

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 133

11/01/2019

Company Report

Pages: 6

Pipeline in a Drug CNS Development Complimented by Trofinetide Pivotal Trial Initiation; Reit Buy and $60 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 134

09/10/2019

Daily Note

Pages: 3

HARMONY Interim Hit Supports Pipeline in a Drug Thesis; Reit Buy and $60 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 135

08/01/2019

Company Report

Pages: 5

Strength in Underlying Business Frames Important Pipeline Catalysts Ahead

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 136

07/23/2019

Daily Note

Pages: 5

Our Thoughts Following the Topline Miss of the Phase 3 ENHANCE study

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 137

05/03/2019

Company Report

Pages: 5

Viewing the Upcoming Schizophrenia Trials Through the Lens of Literature; Reit Buy and $60 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 138

02/27/2019

Company Report

Pages: 6

With Nuplazid Growth Normalizing, We Take a Closer Look at the Schizophrenia Program

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 139

11/07/2018

Company Report

Pages: 6

With a Maturing Catalyst Calendar and Re-Acceleration of Sales, Acadia is Poised to Outperform in 2019, We Believe

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 140

11/01/2018

Daily Note

Pages: 4

Trick or Treat? Stage 1 Results Outweigh Stage 2 Miss, In Our View

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party